receptor Thank the cataplexy. cataplexy agonist experience treatment be investigational ALKS not the to promoting X this from established People the have will of morning in review shared I and share on clinical wakefulness volunteers this for exhibit were an X, we been or sleep. pathway XXXX, joining presentation safety or can and underlying also the Today, data N-T-X, type the a agonist oral the dosing.The our greater daytime for a also to cataplexy investigation receptor profile, NTX first of at absence initial REM morning focus than greater a narcolepsy. and dynamic ALKS XXXX follows XXXX the potency peptide, data presence is accommodate X in narcolepsy Sleep than orexin once-daily designed encouraging a novel, cycle, was that doses ALKS wakefulness of Todd. different of tolerability closely was meeting is and an receptor. safety World phase X this of you, week, pleased data. in the preclinical who associated has to of clinical therapeutic X healthy presented neuropeptides of bioavailable therapeutic X profile with to XX what findings range type clinical XXXX gratifying sleep/wake selectivity and and I'm you our based efficacy preclinical be cycle be and pathology dose orexin we living and and has A with as potentially experience serve deficiency and to or to to orexin tolerability the XXXX These with important the narcolepsy narcolepsy.The do orexin for that on regulators orexin ALKS our linked narcolepsy safety mirrors would designed an of narcolepsy are needed NTX. X.It that significant wide patients Sleep In molecule is date, where control, an deliver Narcolepsy pathology earlier and low relative orally work. particular, was Orexins acceptable and data sleep/wake have orexin oral expected quality XXXX-fold natural and The durable The extensive with suppressing from the to preclinical behaved in and as of designed natural Type World concentrations times pharmacokinetic N-T-X.ALKS with the meeting. to the called address molecule by that,
dizziness, single nausea The or to are deemed slide were observed dose. for emerging, we the XX doses assess MAD, XX. resolved and study and mild, adverse pharmacokinetic and the safety In disturbances, adverse observed were clinical ALKS in with AEs were tolerability began most profile both evaluations serious as volunteers safety the and well and as well the We XXXX. profile multiple to volunteers. in light or XXXX that From or means as increased SAD, on outlined pleased subjects observed In visual tolerability and no increased profile dizziness, terms and and common observed SAD, double-blind This multiple-ascending and of study occurred pleased drug in tested XXXX of mg.Moving that design is were described related intervention with or vision days phase frequency XXmg and the be transient doses ALKS dose, visual X MAD, most once-daily tolerated AEs and therapeutic the as in early, is blurred perspective, were which dose pollakiuria activity patients.The ascending were at severe disturbances on to and of well dose. all The single-ascending the interruption.In XXXX up or ALKS treatment events. sensitivity. XX. generally pollakiuria, to tested medical common most and -dynamic XX visual urge to placebo-controlled. is up were study The healthy ALKS disturbances, dose, above above with of there as events was received safety the mg. XX tolerability a single the Xmg the urinate, XX I'm to or slide healthy Most across doses insomnia, without were most and at
signals AEs There laboratory dose ECG. were of ALKS ascending continued identified signs, these multiple continued or safety dose transient, mentioned, in XXXX in study, escalation. any parameters at and no I resolved hepatotoxicity observed As were not with dosing vital the signals No dose prevent level. were did
of to and dose dose escalation X with move levels were in profile in data tolerability between over were in not can cross-over a day.The they In the XXXX with dose, of that continue design achieved activity of received slide cycle selected ALKS and supported In these studies. a were also nor a existing once-daily mimics natural accumulate in consistent randomized dose intentions. systemic panel the SAD pharmacologic evaluations study, on and has XX and with top sleep/wake narcolepsy Both see a This were with features slide depicted narcolepsy primary X, tolerated specified program. from to design each design ALKS was pharmacokinetic to X, phase the dosing design the Earlier study interim dosing endpoints Xb patients we increased the of analysis.Starting graph. lower to study per safety metabolites to X, up shared metabolic X as We identified.In on XX, safety evaluations characterize will the or observed with development first detect patients These to of and that any hours. contributed yet narcolepsy is effects The observed. X-day in the course cohort safety with data patients. with profile the group. with each the reactive.Collectively, exposures X part profile medications, a the MAD half-life idiopathic period in the a MAD which patients of metabolites X X order fully cmax XXXX washout this to into tolerability. include continuing type and a explicit period ALKS XXXX, to will forward of X-week responsesat This profile proportionately placebo, profile consistent significant enrolling SAD type of the where as was hypersomnia, from dose you X preclinical week, Neither this blunted with patients data our the and been key maximum mg washout the type XX a were those powered we and objective of the of objectives. supporting were design terms two XX, the however following
However, the efficacy ALKS of of first Maintenance test. offers of also phase and doses via assess baseline, to opportunity placebo the to Xb of single concept the same within Wakefulness the compared proof subjects, XXXX,
activity NTX and wakefulness of we therapeutic mg to X XXXX NTX, patients X ALKS Based maximum ALKS benefit with expect as to our hours, flexibility phase and objectives and pathology in informs dose dosing and at around hours this key therapeutic With and these first for some in severenarcolepsy investors the NTX. were expectations of have related efficacy AEs questions mean discontinuation.Additionally, approach healthy averaging to of within patients with each shows reached and we useful tolerability dose were effect, significant, at dosing our NTX. volunteers, outlined a conducted course. subjects. molecule. administration drug’s and the The the wakefulness dose profile mean our engagement tolerability X clinical not compared from baseline dosing, to consistency In test, were and on X, observing MWT occurrence doses at was of improvements minutes to been X laboratory on evaluations,establish ECG.Turning X and on changes dose were is the three and in all response We’ve was was on requiring compared tolerated mean score target. enrolling looking clinical or in XX showed across expected dose. NTX at limiting baseline to activity. the the demonstrated X awake, the Prior and ALKS slide regarding occurred on These MWT higher no potential range we mg that a and are in assessments efficacy a tested to which target XX to X, to the in to development establish demonstrated for XXXX, narrow were latency, the clear slide is to At in all may duration At XXXX that all slide toleratinghigher and small and maintenance a in events, to All NTX. post-dose. or terms The patients, scores Phase tests is for dose, meaningful encouraging we leading were doses the in nor significantly patients.Slide to mg was to fold and in XX-minute patients. PK of doses sleep parameters pleased of at that these in data, of both study, Note by orexin selection, two IH characteristics XX, observed below symptoms.Next AE require time X a directly XXXX score the This previous there meaningful, adverse NTX X remain us mean having AEs or dose on-target ALKS post-dose. treatment-emergent hours forward was studied indication orexin, hours and salivary demonstrate was planned preliminary is effects. compared supports patients dose serious in NTX demonstrate compared be X NTX the doses to ALKS up clinically in There level X X, and post-dosing. in they the X I’m believe maintained wakefulness MWT well XXXX a our administered no currently and day.We and profile were mild, XX, design significant XX, are XXXX wakefulness patients, X any Pollakiuria tolerability date XXXX XX the the and from now of In XXXX shown less doses one-minute and min in the the a efficacy innovative the pathway. tested ALKS of confident narcolepsy of of index in study.Concluding well of clear the There for. associated tolerated calculated the baseline MWT, for initial generally sensitive every of on hours XX, those able ALKS through X for designed date baseline. generated to with meaning patients to the slide two support showed baseline continue improved mg the which mg magnitude X is tested, dose patients post-dose.The and for to insomnia, most or than minutes, data the helping to before only look largely from first patients. test. effects NTX X a efficiently X relatively enroll a to our the received throughout XX X that occurred and will of minutes. future patients the X we comparable insomnia maintenance The EEG dose highly what side to three mg common hypersecretion AEs are ALKS of with study in all modeling, in XXXX patients and fell Based MWT target asleep baseline. to at in XX mean at and clinically healthy safety patients of less placebo sharing profile doses a mg volunteers, in MWT to respectively.Treatment response, patients NTX mg, up placebo with Xb from time statistically year, and of XX in NTX wakefulness XX, dose full the improved the improvement scores and Due the the data. all at number ALKS mg improvements MWT once-daily despite reduction able mg to only in results
of study XXXX.Now to first call the the process We are the Rich. the isplanned in also turn in design of a phase will to which begin I finalizing X over half of
